Performance in Initiating Q1 2017-2018

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:	Errors	Warnings
102762	16/YH/0268	167968	BRAVO part 2 High risk Bladder cancer: A randomised controlled feasibility study of Radical Cystectomy against intra-vesical immunotherapy	No		0	0	48				No		08/07/2016	31/08/2016	12/08/2016	23/09/2016	18/10/2016	21/12/2016	F- No patients seen	No eligible patients seen to date. Low recruitment target.	NHS Provider		
102763	16/EM/0349	211260	A prospective, non-comparative, multicentre study to evaluate a silver coated antimicrobial barrier wound dressing (ACTICOAT™) in the treatment of burns and chronic wounds.	Yes	22/12/2016	0	0		49	48	97	No		21/06/2016	16/09/2016	07/09/2016	24/10/2016	04/11/2016	04/11/2016	D - Sponsor Delays F - No Patients seen J - Other	Amendment to eligibility criteria required. Awaiting approvals.	Sponsor		
102764	16/NW/0305	201856	A Phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of DYSPORT® for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis IPSEN223	Yes	16/06/2017	0	0	0	170	155	325	No		03/05/2016	26/07/2016	20/07/2016	10/01/2017	12/01/2017	30/01/2017	F - No patients seen	Low recruiting study. Few eligible patients and several identified and declined to take part. When we did consent we were the first in UK.	Neither		
102765	16/YH/0520	215388	Streamlining cross-sectional imaging pathways (SCIPs): A feasibility and economic modelling study of point of care	Yes	15/02/2017	0	0	0	17	6	23	Yes		23/01/2017	23/01/2017	20/01/2017	20/01/2017	09/02/2017	09/02/2017			Please Select...		
103746	16/EM/0376	211430	Leadership 301 A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/ Bladder Pain Syndrome Followed by 40-Week Extension Period	No		0	0	0	153			No		16/11/2016	08/12/2016	07/12/2016	19/04/2017	10/05/2017	22/05/2017	F- No patients seen	Low recruiting study. Few eligible patients and several identified and declined to take part.	Neither		
103747	16/NW0517	188554	Myeloma 12 (XII) A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stemcell transplant (ASCT)	No		0	0	0	237			No		28/01/2016	29/07/2016	27/10/2016	29/07/2016	23/03/2017	23/03/2017	D - Sponsor delays	Delay in supply of drugs	Sponsor		